26.04.2022 08:25:01
|
Valneva, Pfizer Report Positive Phase 2 Pediatric Data For Lyme Disease Vaccine Candidate, VLA15
(RTTNews) - Valneva SE (VLA), a specialty vaccine company, and Pfizer Inc. (PFE) reported Tuesday positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.
Based on these new results, the companies plan to proceed with inclusion of pediatric participants in their planned Phase 3 trial.
The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in the third quarter of 2022, subject to regulatory approval.
The Phase 2 trial, VLA15-221, is the first clinical study with VLA15 which enrolled a pediatric population between 5 and 17 years old. It compared the immunogenicity and safety of VLA15 after administration of two or three primary series doses in groups aged 5-11, 12-17 and 18-65 years.
In pediatric participants who received VLA15 in either the two-dose schedule or three-dose schedule, VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested.
Like in adults, the immunogenicity and safety data support a three-dose primary vaccination schedule in pediatric participants in the Phase 3 study.
The companies noted that the safety and tolerability profile observed in the 5- to 17-year age group was similar to the previously reported profile in adult participants. No vaccine-related serious adverse events or SAEs were observed.
Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Valneva SE (spons. ADRs)mehr Nachrichten
05.03.25 |
Erste Schätzungen: Valneva SE (spons ADRs) öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) | |
06.11.24 |
Ausblick: Valneva SE (spons ADRs) mit Zahlen zum abgelaufenen Quartal (finanzen.net) | |
23.10.24 |
Erste Schätzungen: Valneva SE (spons ADRs) legt Quartalsergebnis vor (finanzen.net) |
Analysen zu Pfizer Inc.mehr Analysen
07.03.25 | Pfizer Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
05.02.25 | Pfizer Kaufen | DZ BANK | |
05.02.25 | Pfizer Buy | Goldman Sachs Group Inc. | |
05.02.25 | Pfizer Neutral | UBS AG | |
05.02.25 | Pfizer Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Pfizer Inc. | 23,64 | -0,59% |
|
Valneva SE (spons. ADRs) | 6,25 | 2,46% |
|